Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome
Angela F Journell, Chelsea E Peters, Jessica Meznarich, Sasidhar Goteti, Kalyani Sen · 2026
Read Rivaroxaban as Secondary Thromboprophylaxis in Pediatric Patients With Short Bowel Syndrome by Angela F Journell, Chelsea E Peters, Jessica Meznarich, Sasidhar Goteti, Kalyani Sen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13621405.txt.
Description
Angela F Journell and four colleagues reviewed their center's experience using the blood thinner rivaroxaban in children with short bowel syndrome. These children live on intravenous nutrition through a central line, which raises clot risk, and standard prevention means daily injections families dislike. An oral drug is attractive, yet rivaroxaban absorbs mainly in the stomach, a real question for a shortened gut. Three patients with earlier line-related clots tried it.
Outcomes split three ways. One child developed a new clot while the drug was paused, one suffered a gut bleed, and one finished therapy with no event at all. The authors judge the drug possibly workable in carefully picked patients, provided blood levels are monitored closely. Three cases cannot settle safety or dosing, so they call for larger studies before the practice spreads.
Catalog record
| CREATOR | Angela F Journell, Chelsea E Peters, Jessica Meznarich, Sasidhar Goteti, Kalyani Sen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 15 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |